XML 28 R5.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)
In Thousands
 6 Months Ended 181 Months Ended
Jun. 30, 2011
Jun. 30, 2010
Jun. 30, 2011
Cash flows from operating activities:      
Net loss $ (8,140) $ (9,040) $ (246,446)
Adjustments to reconcile net loss to net cash used in operating activities:      
Accretion of interest on notes payable, net of amortization of debt premium   2 100
Amortization of investment premiums, net     (2,297)
Change in valuation of derivative     308
Change in valuation of warrants (203) 516 (6,273)
Warrant re-pricing     44
Depreciation and amortization 172 240 12,486
Amortization of intangible assets     886
Fixed asset impairment     221
Goodwill and intangibles impairment     7,934
Unrealized foreign exchange loss 21   7,768
Deferred revenue     (98)
Compensation for warrants issued to non employees     1,215
Shares issued for IP rights     446
(Gain) loss on disposal of property, plant and equipment   (9) 99
Stock based compensation 455 786 18,596
Provision for restructuring     1,779
Amortization of issuance costs of Preferred Ordinary "C" shares     2,517
Changes in operating assets and liabilities:      
Prepaid expenses, inventory and other current assets (279) (88) (511)
Accounts payable, accrued liabilities and other current liabilities (482) (2,183) (6,372)
Net cash used in operating activities (8,456) (9,776) (207,598)
Investing activities:      
Purchase of ALIGN     (3,763)
Purchase of property, plant and equipment   (8) (8,831)
Proceeds from sale of property, plant and equipment   35 158
Purchase of short-term investments     (156,657)
Redemptions of short-term investments, net of maturities     162,729
Net cash provided by (used in) investing activities   27 (6,364)
Financing activities:      
Payment of capital lease obligations     (3,719)
Proceeds from issuance of ordinary and preferred ordinary shares, net of issuance costs     121,678
Proceeds from issuance of common stock and warrants, net of issuance costs (80) 15,155 82,324
Net proceeds from stock options and warrants exercised 3 2,700 173
Payment of preferred stock dividend (364)   (1,898)
Repayment of government loan     (455)
Government loan received     414
Loan received from Cyclacel Group Plc     9,103
Proceeds of committable loan notes issued from shareholders     8,883
Loans received from shareholders     1,645
Cash and cash equivalents assumed on stock purchase     17,915
Costs associated with stock purchase     (1,951)
Net cash provided by (used in) financing activities (441) 17,855 234,112
Effect of exchange rate changes on cash and cash equivalents 16 (56) 464
Net increase (decrease) in cash and cash equivalents (8,881) 8,050 20,614
Cash and cash equivalents at beginning of period 29,495 11,493  
Cash and cash equivalents at end of period 20,614 19,543 20,614
Cash received during the period for:      
Interest 11 11 11,726
Taxes   110 17,522
Cash paid during the period for:      
Interest   (187) (1,914)
Schedule of non-cash transactions:      
Acquisitions of equipment purchased through capital leases     3,470
Issuance of common shares in connection with license agreements     592
Issuance of Ordinary shares on conversion of bridging loan     1,638
Issuance of Preferred Ordinary "C" shares on conversion of secured convertible loan notes and accrued interest     8,893
Issuance of Ordinary shares in lieu of cash bonus     164
Issuance of other long term payable on ALIGN acquisition     $ 1,122